A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5081 participants.
Also called NCT01877915
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,081 participants
- Registry
-
NCT01877915 -
2013-000046-19
-
- Other papers using this trial's data
- A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
- Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial
- Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF
- Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01877915. Randomized; quadruple masking; primary purpose treatment. Start 2013-09-10 (actual); primary completion 2018-04-19 (actual). Results posted on 2019-05-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
- Acronym
- COMMANDER HF
- Condition
- Heart Failure
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Placebo
- Intervention (Other)
- Standard of care for heart failure and coronary artery disease
- Lead sponsor
- Janssen Research & Development, LLC
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct01877915- Content hash
b6c14f42f8fb274ddea5fddca4195a64fc739d400fc812e4189f78ce67f5d574